Abstract
SummaryPancreatic proteolytic enzymes are involved in the pathogenesis of acute pancreatitis and may also be responsible for the clinical features of shock and hypotension. A proteolytic enzyme inhibitor, trasylol, is now available for the treatment of pancreatitis. Results of animal experiments are given in which trasylol was found to be effective in preventing the development of hæmorrhagic pancreatitis in dogs. Early clinical experience with trasylol in a few patients with pancreatitis is also presented. The advent of an effective, safe, proteolytic enzyme inhibitor reemphasizes the need for early diagnosis in pancreatitis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
